

CRDP

Provider Bulletin

June 22, 2007

Formulary Updates

EFFECTIVE IMMEDIATELY:

The following medications will be available via the Program's medical exception process:

- Zyvox® will be available only to treat vancomycin resistant enterococcus (VRE). Documentation of the failure of other antibiotics and a copy of the culture and sensitivity report are required for the medical exception to be considered.
- Avelox® will be available when other formulary antibiotics have failed.
- Sensipar® dosing will be increased from the current 90mg per day maximum dosing to 180mg per day. The same criteria still applies.

EFFECTIVE IMMEDIATELY:

- Lyrica® is being added to the CRDP formulary to treat diabetic peripheral neuropathy.

EFFECTIVE JULY 20, 2007:

The following products are removed or restricted to certain patient categories:

- All OTC calcium products containing vitamin D will be removed from the formulary. (Note: calcium as a supplement remains.)
- Neutra-Phos®K and Neutra-Phos® will be available only to transplant patients.

Claim submission questions may be directed to Provider Services at
1-800-835-4080.